Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung‐Hung Su(National Taiwan University), Jia‐Horng Kao(National Taiwan University), Chi‐Yi Chen(National Taiwan University), Tsai‐Yuan Hsieh(Tri-Service General Hospital), Fat‐Moon Suk(Wan Fang Hospital), Chih‐Lin Lin(Chung Shan Medical University Hospital), Ming‐Jong Bair(Mackay Medical College), Rong‐Nan Chien(Keelung Chang Gung Memorial Hospital), Kuo‐Chih Tseng(Buddhist Tzu Chi General Hospital), Tsung‐Hui Hu(National Sun Yat-sen University), Tsung‐Ming Chen(Tungs' Taichung MetroHarbor Hospital), Ming‐Yao Chen(Taipei Medical University-Shuang Ho Hospital), Sheng‐Shun Yang(Taichung Veterans General Hospital), Cheng‐Yuan Peng(China Medical University), Wei‐Wen Su(Changhua Christian Hospital), Yi‐Hsiang Huang(National Yang Ming Chiao Tung University), Chun‐Che Lin(Chung Shan Medical University Hospital), Chia‐Chi Wang(Taipei Tzu Chi Hospital), Tai‐Chung Tseng(National Taiwan University Hospital), Horng‐Yuan Wang(Mackay Memorial Hospital), Chi‐Ling Chen(National Taiwan University), Chi‐Tan Hu(Buddhist Tzu Chi General Hospital), Lein‐Ray Mo(Tainan Municipal Hospital), Yung‐Chao Lei(National Taiwan University Hospital), Yi‐Wen Huang(University of Connecticut), Cheng‐Chao Liang(Far Eastern Memorial Hospital), Shih‐Jer Hsu(National Taiwan University Hospital), Wan‐Long Chuang(Kaohsiung Medical University)
Cited by 221
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569
Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan
|Gastroenterology|2008|547
Hepatogastroenterology
|Hepatogastroenterology|2012|536